Management of Organomegaly with Elevated Tryptase

Initial Evaluation and Diagnosis

The National Comprehensive Cancer Network recommends that a patient presenting with organomegaly and elevated tryptase requires immediate evaluation for systemic mastocytosis, specifically advanced SM with organ damage, which mandates urgent referral to a specialized mastocytosis center and consideration of cytoreductive therapy 1, 2
The combination of organomegaly and elevated tryptase is a red flag for advanced systemic mastocytosis, as organomegaly without organ failure represents a B-finding, while organomegaly with organ dysfunction constitutes a C-finding in the WHO classification system 1, 3

The American College of Physicians suggests documenting the exact serum tryptase level, as levels >200 ng/mL indicate high mast cell burden requiring urgent hematology referral and possible hospitalization, although this specific guideline is from the Journal of the National Comprehensive Cancer Network 4
A complete blood count with differential should be performed to look for cytopenias, which define C-findings 3
A comprehensive metabolic panel should be assessed for hepatic dysfunction and hypoalbuminemia from malabsorption 1, 3
Imaging studies such as CT/MRI or ultrasound of the abdomen/pelvis should be performed to document the extent of organomegaly, lymphadenopathy, and ascites 1

Bone marrow biopsy with comprehensive testing is mandatory when tryptase is elevated and organomegaly is present, as this combination strongly suggests systemic disease 5, 2
The bone marrow workup must include histopathology, immunohistochemistry, flow cytometry, and molecular testing for KIT D816V mutation analysis 5, 2, 1, 6

The presence of ≥2 B-findings upgrades indolent SM to smoldering SM, which has a more guarded prognosis and requires closer monitoring 3
C-findings indicate advanced SM requiring cytoreductive therapy, including hepatomegaly with impaired liver function, palpable splenomegaly with hypersplenism, malabsorption with hypoalbuminemia, cytopenias, weight loss >10% over 6 months, and large osteolytic lesions with or without pathologic fractures 1, 3, 6
The National Comprehensive Cancer Network recommends immediate referral to a specialized mastocytosis center for cytoreductive therapy in patients with C-findings 1, 2
Consider clinical trial enrollment using IWG-MRT-ECNM criteria for organ damage assessment 1

Do not assume elevated tryptase alone indicates mastocytosis severity, as tryptase may be <20 ng/mL in some SM patients with limited disease burden, and conversely, hereditary alpha-tryptasemia can cause baseline elevation without disease 1, 8
Do not delay bone marrow biopsy in patients with organomegaly and elevated tryptase, even if tryptase is only modestly elevated 5, 2
Coordinate with subspecialists including hematology/oncology, gastroenterology, allergy/immunology, and anesthesia for any procedures 1, 2